<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102736</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 16-1580</org_study_id>
    <nct_id>NCT03102736</nct_id>
  </id_info>
  <brief_title>Ketamine and Nitroprusside for Depression</brief_title>
  <official_title>Pharmacologic Attenuation of Ketamine Using Nitroprusside</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects of the medication ketamine and the
      medication called nitroprusside in patients with major depression. Ketamine has both good and
      bad effects. Some studies have shown that ketamine improves depression. However, studies have
      also shown that it causes strange and sometimes unpleasant sensations referred to &quot;psychotic&quot;
      or &quot;dissociative&quot; symptoms. An example of a psychotic symptom would be hearing or seeing
      something that in reality is not there. The study team would like to see if nitroprusside can
      prevent the reported bad effects of ketamine without blocking the reported good effects. This
      might make ketamine a better treatment for depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine is an effective fast-acting therapeutic intervention for patients with treatment
      refractory depression that is known to have the unwanted effect of inducing temporary
      psychotomimetic symptoms (i.e., delusions, hallucinations and thought disorganization) in
      some patients. The precise mechanisms of these psychotropic effects remain to be elucidated,
      but for several decades the NMDA-type glutamate receptor has been hypothesized to be of
      central importance. In this vain, recent studies of the antihypertensive agent nitroprusside
      - which increases the availability of the molecular nitric oxide, a known by-product of NMDA
      activity - have found evidence for antipsychotic properties both in humans with psychotic
      illness and healthy subjects given ketamine. Here, the clinical team proposes a study that
      will build on this work by evaluate the effects of nitroprusside on both the antidepressant
      and psychotomimetic effects of ketamine given to patients to treat refractory depression. In
      addition, as an exploratory aim, by collecting serial blood samples from the subjects, as the
      subjects are administered ketamine and nitroprusside, the clinical team will seek to
      determine functional markers of therapeutic effect and the mechanisms by which ketamine
      modulates both mood and psychotic states Research Question: The clinical team will test
      whether the effects of ketamine (KET) on mood and psychotic states is modified by
      co-administration with sodium nitroprusside (NP) in patients with depression. Furthermore,
      the clinical team will evaluate the extent to which the underlying biology of disease states
      and drug mechanisms can be inferred through analysis of brain-derived molecular material
      isolated from the peripheral circulation.

      Specific Aims:

      Aim I. To test whether co-administration with NP has any impact on the efficacy of KET as an
      antidepressant.

      Aim II: To test the ability of NP to prevent the psychotomimetic effects of KET in patients
      with depression.

      Research Hypotheses:

      Research Hypothesis I. Patients pre-treated with NP will experience attenuated antidepressant
      effects (measured by MADRS score) following KET compared to pre-treatment with placebo.

      Research Hypothesis II: Patients pre-treated with NP will experience attenuated
      psychotomimetic effects (e.g., CADSS score) immediately following KET compared to
      pre-treatment with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">June 12, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Both participants and research staff (aside from pharmacy) will be blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale</measure>
    <time_frame>24 hours after start of infusion</time_frame>
    <description>This is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 (normal) and 60 (severe depression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician-Administered Dissociative States Scale</measure>
    <time_frame>240 minutes after start of infusion</time_frame>
    <description>This is used to measure dissociative effects during the infusions. The scale includes 23 clinician administered items scored from 0 (not at all) to 4 (extremely). The CADSS measures impairment in body perception, environmental perception, time perception, memory impairment, and feelings of unreality. Full scale from 0-92, with lower score indicating better health outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>240 minutes after start of infusion</time_frame>
    <description>These scales are scored in millimeters from the left-hand side of a 100-mm line to a perpendicular mark made by the patient at a point corresponding to the apparent magnitude of the feeling state. Range: 0 (&quot;not at all&quot;) to 100 (&quot;most ever&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>+240 minutes (after start of Placebo/Nitroprusside infusion)</time_frame>
    <description>BPRS used to assess acute behavioral changes during the infusions. Four key BPRS items for the positive (+) symptoms of psychosis will be used: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content. Three items representing the negative (-) symptoms of psychosis will also be used: blunted affect, emotional withdrawal, and motor retardation. Each item scored 1-7. Full scale from 7 - 49, with higher score indicating more symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Placebo and Ketamine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over 40 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitroprusside and Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo saline</description>
    <arm_group_label>Placebo and Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.5 mg/kg ketamine</description>
    <arm_group_label>Nitroprusside and Ketamine</arm_group_label>
    <arm_group_label>Placebo and Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroprusside</intervention_name>
    <description>0.5 mcg/kg nitroprusside</description>
    <arm_group_label>Nitroprusside and Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, 21-65 years of age;

          -  Female individuals who are not of childbearing potential (i.e., surgically sterile,
             postmenopausal for at least one year) or using a medically accepted reliable means of
             contraception. Women using oral contraceptive medication for birth control must also
             be using a barrier contraceptive. Women of childbearing potential must also have a
             negative pregnancy test at screening and at pre-infusion;

          -  Participants must fulfill current DSM-5 criteria for Major Depression without
             psychotic features or Persistent Depressive Disorder with specifier of &quot;with
             persistent major depressive episode&quot;;

          -  Depression is at least moderate severity, defined as a CGI-S score of ≥ 4;

          -  Current major depressive episode is of at least 4 weeks duration

          -  Each participant must have a level of understanding sufficient to agree to all tests
             and examinations required by the protocol and must sign an informed consent document

          -  Each participant must be able to identify a family member, physician, or friend who
             will act as an emergency contact

        Exclusion Criteria:

          -  Lifetime history of psychotic features, diagnosis of schizophrenia or any other
             psychotic disorder, or diagnosis of bipolar disorder;

          -  Lifetime histories of autism, mental retardation, pervasive developmental disorders,
             or Tourette's syndrome;

          -  Current diagnosis of obsessive compulsive disorder (OCD) or eating disorder (bulimia
             nervosa or anorexia nervosa);

          -  Subjects with DSM-V drug or alcohol abuse/dependence within the preceding 2 years;

          -  Patients with schizotypal or antisocial personality disorder, or any clinically
             significant axis II disorder that would, in the investigator's judgment, preclude safe
             study participation;

          -  Patients judged clinically to be at serious and imminent suicidal or homicidal risk;

          -  Women who are either pregnant or nursing;

          -  Any serious, unstable medical illnesses including hepatic, renal impairment,
             gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic,
             immunologic, or hematologic disease;

          -  History of congestive heart failure or established coronary artery disease;

          -  History of cerebrovascular insufficiency

          -  History of intrapulmonary arteriovenous shunts, co-arctation of the aorta or other
             conditions where cardiac outflow tract is obstructed;

          -  Vitamin B12 deficiency;

          -  Clinically significant abnormal findings of laboratory parameters, physical
             examination, or ECG;

          -  Renal impairment, as reflected by a BUN &gt; 20 mg/dL and/or creatinin clearance of &gt;1.3
             mg/dL;

          -  Thyroid impairment, as reflected by a thyroid-stimulating hormone (TSH) &gt; 4.2 mU/L;

          -  Hepatic injury, as reflected by AST or ALT greater than twice the upper limit of the
             reference range (AST: &gt;80; ALT &gt;110)

          -  Patients who have a positive urine toxicology for illicit substances at screening and
             within 24 hours of the infusion;

          -  Treatment with an irreversible MAOI within 2 weeks prior to randomization or
             fluoxetine within 4 weeks prior to randomization;

          -  Treatment with other antidepressants (classified as SSRIs, SNRIs, Atypical
             Antidepressants, MAOIs, TCAs) within one week of randomization.

          -  Previous recreational use of phencyclidine (PCP) or KET;

          -  Hypertension with systolic BP &gt;160 mm Hg or diastolic BP &gt;90 mm Hg at screening,
             systolic BP &gt; 165 mm Hg or diastolic BP &gt; 95 mm Hg immediately prior to treatment with
             study drug or hypotension with systolic BP &lt; 90 or diastolic &lt; 60 at screening or
             immediately prior to treatment with study drug; heart rate &gt;110 or &lt;60 at either of
             these time points;

          -  Treatment with sildenafil (Viagra), tadalafil (Cialis), Avanafil (Stendra), Vardenafil
             (Levitra) or other drugs in the same category of phosphodiesterase-5 enzyme inhibitors
             within 2 weeks of infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Murrough, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <results_first_submitted>June 14, 2020</results_first_submitted>
  <results_first_submitted_qc>July 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2020</results_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>James Murrough</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>ketamine</keyword>
  <keyword>nitroprusside</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03102736/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>40 participants enrolled, 14 were excluded before starting the study and 10 were excluded after starting the study but before randomization (6 were ketamine non-responder, 2, failed to return to baseline, and 2 withdrew before randomization)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo and Ketamine</title>
          <description>Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over the last 40 minutes of the infusion</description>
        </group>
        <group group_id="P2">
          <title>Nitroprusside and Ketamine</title>
          <description>0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo and Ketamine</title>
          <description>Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over the last 40 minutes of the infusion</description>
        </group>
        <group group_id="B2">
          <title>Nitroprusside and Ketamine</title>
          <description>0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" spread="3.1"/>
                    <measurement group_id="B2" value="42.9" spread="11.7"/>
                    <measurement group_id="B3" value="37.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MADRS</title>
          <description>Montgomery-Asberg Depression Rating Scale - This is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 (normal) and 60 (severe depression).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" spread="5.3"/>
                    <measurement group_id="B2" value="26.9" spread="4.4"/>
                    <measurement group_id="B3" value="28.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QIDS</title>
          <description>Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) score - Each item is rated 0 (no depression) to 3 (severe depression). The total score ranges from 0-27, with higher score indicating more symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.6" spread="3.6"/>
                    <measurement group_id="B2" value="14.3" spread="2.5"/>
                    <measurement group_id="B3" value="15.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI-S</title>
          <description>The Clinical Global Impression – Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Full scale from 1-7, with higher score indication more symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="0.8"/>
                    <measurement group_id="B2" value="4.4" spread="0.5"/>
                    <measurement group_id="B3" value="4.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery-Asberg Depression Rating Scale</title>
        <description>This is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 (normal) and 60 (severe depression).</description>
        <time_frame>24 hours after start of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Ketamine</title>
            <description>Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over the last 40 minutes of the infusion</description>
          </group>
          <group group_id="O2">
            <title>Nitroprusside and Ketamine</title>
            <description>0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale</title>
          <description>This is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 (normal) and 60 (severe depression).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="11.9"/>
                    <measurement group_id="O2" value="14.2" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician-Administered Dissociative States Scale</title>
        <description>This is used to measure dissociative effects during the infusions. The scale includes 23 clinician administered items scored from 0 (not at all) to 4 (extremely). The CADSS measures impairment in body perception, environmental perception, time perception, memory impairment, and feelings of unreality. Full scale from 0-92, with lower score indicating better health outcomes.</description>
        <time_frame>240 minutes after start of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Ketamine</title>
            <description>Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over the last 40 minutes of the infusion</description>
          </group>
          <group group_id="O2">
            <title>Nitroprusside and Ketamine</title>
            <description>0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-Administered Dissociative States Scale</title>
          <description>This is used to measure dissociative effects during the infusions. The scale includes 23 clinician administered items scored from 0 (not at all) to 4 (extremely). The CADSS measures impairment in body perception, environmental perception, time perception, memory impairment, and feelings of unreality. Full scale from 0-92, with lower score indicating better health outcomes.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="9.9"/>
                    <measurement group_id="O2" value="8.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale</title>
        <description>These scales are scored in millimeters from the left-hand side of a 100-mm line to a perpendicular mark made by the patient at a point corresponding to the apparent magnitude of the feeling state. Range: 0 (&quot;not at all&quot;) to 100 (&quot;most ever&quot;).</description>
        <time_frame>240 minutes after start of infusion</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Ketamine</title>
            <description>Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over the last 40 minutes of the infusion</description>
          </group>
          <group group_id="O2">
            <title>Nitroprusside and Ketamine</title>
            <description>0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale</title>
          <description>These scales are scored in millimeters from the left-hand side of a 100-mm line to a perpendicular mark made by the patient at a point corresponding to the apparent magnitude of the feeling state. Range: 0 (&quot;not at all&quot;) to 100 (&quot;most ever&quot;).</description>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Psychiatric Rating Scale (BPRS)</title>
        <description>BPRS used to assess acute behavioral changes during the infusions. Four key BPRS items for the positive (+) symptoms of psychosis will be used: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content. Three items representing the negative (-) symptoms of psychosis will also be used: blunted affect, emotional withdrawal, and motor retardation. Each item scored 1-7. Full scale from 7 - 49, with higher score indicating more symptoms.</description>
        <time_frame>+240 minutes (after start of Placebo/Nitroprusside infusion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Ketamine</title>
            <description>Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over the last 40 minutes of the infusion</description>
          </group>
          <group group_id="O2">
            <title>Nitroprusside and Ketamine</title>
            <description>0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Psychiatric Rating Scale (BPRS)</title>
          <description>BPRS used to assess acute behavioral changes during the infusions. Four key BPRS items for the positive (+) symptoms of psychosis will be used: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content. Three items representing the negative (-) symptoms of psychosis will also be used: blunted affect, emotional withdrawal, and motor retardation. Each item scored 1-7. Full scale from 7 - 49, with higher score indicating more symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="1.13"/>
                    <measurement group_id="O2" value="7.2" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours after infusion</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo and Ketamine</title>
          <description>Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over the last 40 minutes of the infusion</description>
        </group>
        <group group_id="E2">
          <title>Nitroprusside and Ketamine</title>
          <description>0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Aches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Worsening MDD</sub_title>
                <description>Major Depressive Disorder</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Murrough</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-585-1640</phone>
      <email>james.murrough@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

